0
Abstract: Poster Presentations |

ASSESSMENT OF PATIENT SYMPTOM AND FUNCTIONING OUTCOMES AMONG COPD SUBJECTS TREATED WITH ARFORMOTEROL OR RACEMIC FORMOTEROL: A 6-MONTH CLINICAL TRIAL FREE TO VIEW

Frank Sciurba, MD*; Claudia Cote, MD; Kenneth Sciarappa, PhD; Elizabeth Goodwin, PhD; Lisa Curry, BS; John Hanrahan, MD
Author and Funding Information

University of Pittsburgh, Pittsburgh, PA


Chest


Chest. 2008;134(4_MeetingAbstracts):p16002. doi:10.1378/chest.134.4_MeetingAbstracts.p16002
Text Size: A A A
Published online

Abstract

PURPOSE: The impact of treatment with the long-term acting β2-agonists (LABAs) arformoterol (administered via nebulization) and racemic formoterol dry powder inhaler (DPI) on symptom and functioning outcomes in 443 subjects with COPD was evaluated.

METHODS: COPD subjects (mean FEV1 1.21 L, ∼41.0 % predicted) were randomized to receive nebulized arformoterol (15μg BID [n=149] or 25μg BID [n=147]) or formoterol 12μg BID [n=147]) for 6-months in a multi-center, double-blind, randomized trial. The effect of treatment on dyspnea (Baseline Dyspnea Index [BDI]/Transition Dyspnea Index [TDI]), and patient clinical status (St. George Respiratory Questionnaire [SGRQ], and BODE scores) were evaluated.

RESULTS: Mean (±SD) BDI was not different between treatment groups (ranged 5.1±2.4 to 5.3±2.2). Mean (±SD) TDI focal score improved significantly but similarly for all treatment groups at 13 weeks (range 1.5±2.6 to 1.6±2.7) and at 6-months (range: 1.4±2.8 to 1.5±2.8). At the end of 6-months, 48.0% to 52.4% of subjects had ≥1 unit improvement in TDI. Mean (±SD) baseline SGRQ total score was also similar for all treatment groups (range: 48.9±14.9 to 52.4±17.7). Mean (±SD) SGRQ total score improved significantly from baseline for the three treatment groups, both at 13-weeks (range: −1.9±9.9 to −4.2±10.1) and at 6-months (range: −3.7±11.8 to −6.8±10.1). At 6-months, 43.3% to 56.7% of subjects improved by ≥4 units. BODE scores were similar at baseline among treatment groups (Mean ± SD range: 4.8±1.6 to 5.1±1.7), and improved significantly but similarly from baseline for all treatment groups at 13 weeks (range: −0.6±1.5 to −0.9±1.3) and 6-months (range: −0.8±1.5 to −1.1±1.5).

CONCLUSION: In this study, 6-month maintenance LABA treatment (nebulized arformoterol or formoterol DPI) of subjects with COPD was associated with improvement in TDI, SRGQ, and BODE indexes over 6-months.

CLINICAL IMPLICATIONS: Long-term maintenance use of the LABAs arformoterol and formoterol improves dyspnea, measures of health status and functioning in COPD subjects.Support for this study provided by Sepracor Inc.

DISCLOSURE: Frank Sciurba, No Financial Disclosure Information; No Product/Research Disclosure Information

Tuesday, October 28, 2008

1:00 PM - 2:15 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543